Federal Judge to Rule on Telemedicine Abortion Access Amid Stable National Rates
A federal judge is expected to issue a ruling on a legal challenge against the Food and Drug Administration's (FDA) 2023 rule, which permits the prescription of mifepristone via telemedicine and its dispensing by mail. This legal development occurs as recent data indicates that the number of abortions performed by clinicians in the U.S. has remained stable, a trend partly attributed to increased access through telemedicine following the 2022 reversal of Roe v. Wade.
The number of abortions performed by clinicians in the U.S. has remained stable, a trend partly attributed to increased access through telemedicine following the 2022 reversal of Roe v. Wade.
Mifepristone: A Key Medication and Evolving Access
Mifepristone, a medication used for over 25 years in the U.S. for first-trimester abortion and miscarriage management, is widely regarded as safe and effective by the medical community. The FDA has historically adjusted its regulations regarding access to this medication.
In 2023, under President Biden's administration, the FDA altered its rules to allow mifepristone to be prescribed without an in-person appointment and subsequently dispensed by mail. This change marked a significant shift in access policy for the medication.
Legal Battle Over FDA's Mifepristone Policy
The state of Louisiana, joined by a Louisiana patient, initiated a lawsuit challenging the FDA's 2023 rule alteration. The lawsuit, known as Louisiana v. FDA, awaits a decision from a federal judge.
Louisiana Attorney General Liz Murrill stated in January that FDA rules require modification to address concerns.
Opponents of abortion access have voiced concerns regarding the FDA's policy changes, with several legal challenges and a Congressional bill aiming to prevent the mailing of mifepristone to patients. In contrast, misoprostol, another medication used in abortion and for ulcer prevention, faces fewer attempts at restriction.
National Trends: Stable Abortion Rates Amidst Policy Shifts
Despite the enactment of state-level bans and restrictions since the 2022 reversal of Roe v. Wade, the number of abortions performed by clinicians in the U.S. has remained stable. A report from the Guttmacher Institute, an organization supporting abortion access, estimated approximately 1,126,000 abortions were provided in the U.S. in 2025, a figure consistent with 2024.
Isaac Maddow-Zimet, a data scientist at the institute, highlighted this consistency, noting the significant role telemedicine has played in maintaining abortion access.
States that support abortion access have implemented "shield laws" designed to protect healthcare providers from legal risks when prescribing medication to patients residing in states with abortion bans. This development has contributed to an increase in individuals in states with restrictions accessing abortions via telemedicine.
Overall, 91,000 patients in states with bans reportedly received telehealth abortions in 2025.
For example, the Guttmacher report indicated an increase in abortions in Louisiana, from approximately 2,500 in 2023 to over 9,000 in the following year. The availability of telehealth services has also been associated with a reduced need for individuals to travel across state lines for care.